Results 31 to 40 of about 3,006,184 (303)

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms [PDF]

, 2015
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,
Aranaz, P., Aranaz, P., Bandinelli, S., Bandinelli, S., Barosi, G., Barosi, G., Baxter, E.J., Baxter, E.J., Callaway, A., Callaway, A., Campbell P., Campbell P., Cazzola, M., Cazzola, M., Chase, A., Chase, A., Chen, E., Chen, E., Cross N.C., Cross N.C., Dohner, K., Dohner, K., Duncombe, A.S., Duncombe, A.S., Evans, P., Evans, P., Ewing, J., Ewing, J., Gale, R.E., Gale, R.E., Giannopoulos, A., Giannopoulos, A., Gisslinger, H., Gisslinger, H., Godfrey, A.L., Godfrey, A.L., Grallert, H., Grallert, H., Green, A.R., Green, A.R., Griffiths, M., Griffiths, M., Guglielmelli, P., Guglielmelli, P., Haferlach, T., Haferlach, T., Harrison, C., Harrison, C., Harutyunyan, A.S., Harutyunyan, A.S., Jack, A., Jack, A., Jones, A.V., Jones, A.V., Kralovics, R., Kralovics, R., Leung, W., Leung, W., Lin, F., Lin, F., Maclean, C., Maclean, C., Mannarelli, C., Mannarelli, C., Mead, A.J., Mead, A.J., Nangalia, J., Nangalia, J., Oscier, D., Oscier, D., Pieri, L., Pieri, L., Reiter, A., Reiter, A., Schnittger, S., Schnittger, S., Schuh, A., Schuh, A., Short, M., Short, M., Stegelmann, F., Stegelmann, F., Strauch, K., Strauch, K., Tanaka, T., Tanaka, T., Tapper, W., Tapper, W., Vannucchi, A., Vannucchi, A., Waghorn, K., Waghorn, K., Wallis, L., Wallis, L., Ward, D., Ward, D., White, H.E., White, H.E., Zoi, K., Zoi, K.   +99 more
core   +5 more sources

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

Haematologica, 2018
Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders.
Chi Hua Sarah Lin, Yu Zhang, Kenneth Kaushansky, Huichun Zhan   +3 more
doaj   +1 more source

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W, Ding, L-W, Doan, NB, Dong, X-M, Garg, M, Gery, S, Hattori, N, Huang, RY-J, Koeffler, HP, Lin, D-C, Liu, L-Z, Meng, X, Said, JW, Sun, Q-Y, Tang, K, Xiao, J-F, Yang, H   +16 more
core   +2 more sources

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

Haematologica, 2008
Background The JAK2 V617F mutation can be found in patients with polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. Mutation or methylation of other components of JAK/STAT signaling, such as the negative regulators suppressor of ...
Nasios Fourouclas, Juan Li, Daniel C. Gilby, Peter J. Campbell, Philip A. Beer, Elaine M. Boyd, Anne C. Goodeve, David Bareford, Claire N. Harrison, John T. Reilly, Anthony R. Green, Anthony J. Bench   +11 more
doaj   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo, Barbui, Tiziano, Beggiato, Eloise, Bellini, Marta, Bertozzi, Irene, Betti, Silvia, Bonifacio, Massimiliano, Cacciola, Emma, Cacciola, Rossella, Carli, Giuseppe, Carobbio, Alessandra, Cattaneo, Daniele, Cazzola, Mario, Censori, Bruno, Cervantes, Francisco, Cortelezzi, Agostino, De Stefano, Valerio, Di Lazzaro, Vincenzo, Elli, Elena Maria, Ellis, Martin H., Finazzi, Guido, Finazzi, Maria Chiara, Gaidano, Gianluca, Gomez, Montse, Griesshammer, Martin, Guglielmelli, Paola, Hernandez-Boluda, Juan-Carlos, Iurlo, Alessandra, Loscocco, Giuseppe Gaetano, Lunghi, Francesca, Miroslava, Palova, Musolino, Caterina, Palandri, Francesca, Randi, Maria Luigia, Rapezzi, Davide, Rossi, Elena, Rumi, Elisa, Sadjadian, Parvis, Scaffidi, Luigi, Tieghi, Alessia, Vannucchi, Alessandro M., Vianelli, Nicola   +41 more
core   +5 more sources

A rare case of late myelodysplasia cutis associated with essential thrombocythemia: A case report

SAGE Open Medical Case Reports, 2022
Myelodysplasia cutis is a relatively new described entity that is characterized by cutaneous plaques and nodules representing dermal infiltration of myeloid immature non-blastic cells.
Suzel Fournier, Sylvain Mailhot, Janie Bujold   +2 more
doaj   +1 more source

Platelets as mediators of Thromboinflammation in chronic Myeloproliferative Neoplasms [PDF]

, 2019
Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood cell counts.
Heller, Paula Graciela, Marin Oyarzún, Cecilia Paola   +1 more
core   +1 more source

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

BMC Medical Genomics, 2019
Background Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy.
Alexander V. Lavrov, Ekaterina Yu. Chelysheva, Elmira P. Adilgereeva, Oleg A. Shukhov, Svetlana A. Smirnikhina, Konstantin S. Kochergin-Nikitsky, Valentina D. Yakushina, Grigory A. Tsaur, Sergey V. Mordanov, Anna G. Turkina, Sergey I. Kutsev   +10 more
doaj   +1 more source

Failure of Splenectomy to Ameliorate Portal Hypertension in Myeloproliferative Disorders

Canadian Journal of Gastroenterology, 1994
The correct treatment of portal hypertension associated with myeloproliferative disorders remains uncertain. Splenectomy has been advocated by some to eliminate the forward flow component of the portal hypertension and thus reduce portal pressure.
Samuel S Lee, Guido Van Rosendaal, Thomas E Lay, James K Kelly, Graham F Pineo   +4 more
doaj   +1 more source

Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Indian Journal of Medical and Paediatric Oncology, 2015
According to the 2008 revision of the World Health Organization (WHO) classification of myeloid malignancies, philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) include clonal, hematologic disorders such as polycythemia vera ...
M B Agarwal, Hemant Malhotra, Prantar Chakrabarti, Neelam Varma, Vikram Mathews, Jina Bhattacharyya, Tulika Seth, K Gayathri, Hari Menon, P G Subramanian, Ajay Sharma, Maitreyee Bhattacharyya, Jay Mehta, A K Vaid, Sandeep Shah, Shyam Aggarwal, P K Gogoi, Reena Nair, Usha Agarwal, Subhash Varma, S. V. S. S. Prasad, Marie Therese Manipadam   +21 more
doaj   +1 more source